Research Context
The GLOW STACK is a highly sought-after combination of research compounds — GHK-Cu, BPC, and TB — formulated for skin, connective-tissue, and recovery research models. Each component is supplied at >99% HPLC purity.
The GLOW STACK sits alongside the KLOW STACK and WOLVERINE STACK as one of the most-referenced multi-peptide stacks in regenerative research. These research peptides are widely cataloged as foundational compounds in the recovery class.
A stack/blend combining GHK-Cu, BPC-157, and TB-500. Formulated for skin, connective-tissue, and recovery research.
GLOW STACK: GHK-Cu/BPC-157/TB-500 Triple-Peptide Research Complex
The GLOW STACK is a proprietary triple-peptide research formulation combining GHK-Cu (Copper Tripeptide-1), BPC-157 (Body Protection Compound-157), and TB-500 (Thymosin Beta-4). This GLOW blend is specifically engineered for research models investigating dermal regeneration, extracellular matrix (ECM) remodeling, collagen synthesis, and cutaneous wound healing. The GLOW STACK is widely studied alongside the KLOW STACK (which adds KPV for mucosal and anti-inflammatory pathways) and the WOLVERINE STACK (which focuses on connective tissue without GHK-Cu).
GHK-Cu serves as the distinguishing component of the GLOW STACK, providing copper-dependent signaling for collagen I, III, and elastin synthesis. BPC-157 and TB-500 contribute complementary tissue repair and angiogenic mechanisms.
This tri-peptide synergy is of particular interest in anti-aging research, dermatological studies, and wound healing models. Investigators looking to buy research-grade GLOW Stack typically source mg-dosed material with batch-specific HPLC purity and Certificate of Analysis documentation. SCYRX offers the GLOW Stack for sale exclusively to qualified researchers and institutions for laboratory research purposes only.
All components of the GLOW blend are supplied at ≥99% HPLC purity with batch-matched third-party Certificates of Analysis. The GLOW STACK is intended for laboratory research purposes only and is not approved for human use.
Individual Component Research Mechanisms
GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex) is a naturally occurring tripeptide that functions as a copper delivery system and signaling molecule. Research demonstrates its ability to activate matrix metalloproteinases (MMP-2 and MMP-9) for extracellular matrix remodeling, upregulate collagen I and III synthesis in dermal fibroblasts, stimulate elastin production, and promote glycosaminoglycan synthesis. GHK-Cu also exhibits antioxidant activity through copper-dependent superoxide dismutase (SOD) activation and modulates gene expression related to tissue repair and anti-aging pathways.
BPC-157 is a 15-amino-acid peptide derived from human gastric juice. Research highlights its role in tissue repair through VEGF (Vascular Endothelial Growth Factor) receptor upregulation, nitric oxide pathway modulation, and enhanced angiogenesis. In the context of the GLOW STACK, BPC-157 contributes to dermal wound healing, mucosal protection, and connective tissue repair through mechanisms that complement GHK-Cu's collagen-stimulating effects.
TB-500 is the synthetic version of the 43-amino-acid peptide Thymosin Beta-4. Research focuses on its role in regulating actin cytoskeleton dynamics through G-actin sequestration, promoting cell migration to injury sites, stimulating angiogenesis, and reducing fibrosis and scar tissue formation. In the GLOW STACK, TB-500 enhances the regenerative environment by improving cellular recruitment and blood vessel formation, working synergistically with GHK-Cu's matrix remodeling effects.
GLOW STACK Research Applications
Dermal Regeneration and Skin Research
The GLOW STACK is frequently selected for research models investigating skin regeneration, photoaging reversal, and dermal thickness restoration. GHK-Cu's stimulation of collagen and elastin synthesis, combined with BPC-157 and TB-500's wound healing and angiogenic effects, creates a comprehensive approach to cutaneous tissue repair. Studies demonstrate improvements in skin elasticity, reduced wrinkle depth, and enhanced wound closure rates in animal models.
Extracellular Matrix Remodeling
The GLOW STACK is investigated for its ability to modulate extracellular matrix composition and structure. GHK-Cu activates MMPs for controlled matrix degradation and remodeling, while simultaneously stimulating new collagen and proteoglycan synthesis. This dual action is of interest in research on scar tissue reduction, tissue fibrosis, and age-related matrix degradation.
Wound Healing and Tissue Repair
The combination of BPC-157's angiogenic and mucosal healing properties with TB-500's cell migration and anti-fibrotic effects, enhanced by GHK-Cu's matrix support, makes the GLOW blend a comprehensive tool for wound healing research. Studies investigate its effects on wound closure rate, granulation tissue formation, re-epithelialization, and scar quality.
Anti-Aging and Cellular Rejuvenation
GHK-Cu has been extensively studied for its anti-aging effects, including gene expression changes that reverse age-related cellular decline. Research demonstrates GHK-Cu can restore youthful gene expression patterns in fibroblasts, increase stem cell marker expression, and reduce senescence markers. When combined with BPC-157 and TB-500, the GLOW STACK provides a multi-pathway approach to investigating age-related tissue deterioration.
GLOW STACK vs. KLOW STACK vs. WOLVERINE STACK: Comparative Analysis
| Feature | GLOW STACK | KLOW STACK | WOLVERINE STACK |
|---|---|---|---|
| Peptide Composition | GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg) | GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), KPV (10mg) | BPC-157, TB-500 (1:1 ratio) |
| Total Peptide Content | 70mg | 80mg | 10mg or 20mg (varies by vial size) |
| Primary Research Focus | Dermal regeneration, ECM remodeling, collagen synthesis | Dermal regeneration plus mucosal and anti-inflammatory pathways | Connective tissue repair, musculoskeletal healing |
| Key Distinguishing Component | GHK-Cu (copper peptide for collagen/elastin) | GHK-Cu plus KPV (anti-inflammatory tripeptide) | Standard-dose BPC-157 and TB-500 in 1:1 ratio (no GHK-Cu or KPV) |
| Angiogenesis Support | Yes (BPC-157, TB-500) | Yes (BPC-157, TB-500) | Yes (BPC-157, TB-500) |
| Collagen Synthesis | Yes (GHK-Cu) | Yes (GHK-Cu) | No (no GHK-Cu) |
| Anti-Inflammatory Pathway | Mild (GHK-Cu antioxidant) | Strong (KPV NF-kB inhibition) | Minimal |
| Mucosal Protection | Mild (BPC-157) | Strong (KPV plus BPC-157) | Moderate (BPC-157) |
| Anti-Fibrotic Effects | Yes (TB-500) | Yes (TB-500, KPV) | Yes (TB-500) |
Note: WOLVERINE STACK is available in 10mg vials (5mg BPC-157 + 5mg TB-500) or 20mg vials (10mg BPC-157 + 10mg TB-500). Formulation ratios and total peptide content may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition.
GLOW STACK Chemical Specifications
| Specification | Value |
|---|---|
| Peptide Components | GHK-Cu, BPC-157, TB-500 |
| GHK-Cu CAS Number | 49557-75-7 |
| GHK-Cu Molecular Formula | C₁₄H₂₄CuN₆O₄ |
| BPC-157 CAS Number | 137525-51-0 |
| BPC-157 Molecular Formula | C₆₂H₉₈N₁₆O₁₁ |
| TB-500 CAS Number | 77095-66-2 |
| TB-500 Molecular Formula | C₂₁₂H₃₅₀N₅₆O₇₈S |
| Typical Total Content | 70mg (may vary by batch) |
| Purity | ≥99% by HPLC |
| Form | Lyophilized white powder |
Note: Formulation ratios and purity metrics may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition and laboratory-verified specifications.
Storage and Stability
Lyophilized GLOW STACK should typically be stored at −20 °C in a tightly sealed container, protected from light and moisture. Under these conditions, it generally remains stable for up to 24 months from the manufacture date.
The lyophilized GLOW blend can typically be shipped at room temperature for short periods (up to two weeks) without significant degradation, though refrigerated shipping is preferred for long-distance transport.
Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2–8 °C and typically used within 28 days. Researchers should avoid repeated freeze-thaw cycles and vigorous shaking to maintain peptide integrity. GHK-Cu may impart a slight blue-green color to the reconstituted solution due to the copper complex, which is normal.
Research Protocol Considerations
Reconstitution. The GLOW STACK is typically reconstituted with bacteriostatic water. Typical reconstitution volumes range from 1–3 mL depending on desired concentration. Because the stack contains multiple peptides with different molecular weights, researchers should be aware that the final concentration of each individual peptide will vary based on its proportion in the blend.
Complementary Research. Investigators studying comprehensive dermal or anti-aging protocols often research the GLOW STACK alongside metabolic compounds like Semaglutide and RETA20, hormonal peptides like CJC-1295 and Ipamorelin, or other regenerative compounds. Researchers wanting to add mucosal anti-inflammatory pathways often compare the GLOW STACK to the KLOW STACK, which includes KPV.
Research Dosing Considerations
In preclinical research models, the GLOW Stack is evaluated in milligram (mg) quantities reflecting the combined 70 mg total peptide content per vial. Reported in vitro and in vivo investigations typically allocate the dissolved volume across multiple study time points so that individual GHK-Cu, BPC-157, and TB-500 exposure aligns with each peptide's published research range. Exact mg-scale allocations should be determined by the principal investigator based on study endpoints, model system, and institutional protocol.
Related Research Peptides
GLOW STACK Research FAQ
Is the GLOW Stack legal for research purposes?
Yes. The GLOW Stack sold by SCYRX is intended strictly for in vitro laboratory research and is not for human or veterinary use. All products are sold to licensed researchers and institutions for laboratory research purposes only.
Can the components of GLOW STACK be separated after reconstitution?
No. Once the lyophilized blend is reconstituted, the peptides are in solution together and cannot be physically separated for individual dosing. Researchers requiring individual peptide dosing should purchase separate vials of GHK-Cu, BPC-157, and TB-500.
How does GLOW STACK differ from KLOW STACK?
The GLOW STACK contains three peptides (GHK-Cu, BPC-157, TB-500) focused on dermal regeneration and extracellular matrix remodeling. The KLOW STACK adds KPV (10mg) to provide additional mucosal protection and anti-inflammatory effects through NF-kB pathway inhibition. Researchers select GLOW when dermal and collagen endpoints are the primary focus, while KLOW is selected when mucosal and inflammatory pathways are also of interest.
Why does the reconstituted solution have a blue-green color?
The blue-green coloration is due to the presence of GHK-Cu (Copper Tripeptide-1), which naturally exhibits this color due to the copper complex. This is normal and indicates the presence of the copper peptide component.
What research models commonly utilize GLOW STACK?
The GLOW STACK is frequently selected for in vitro and in vivo studies investigating skin aging, photoaging, dermal wound healing, extracellular matrix remodeling, collagen synthesis, scar reduction, and cutaneous tissue regeneration. It is also studied in models of surgical wound healing and burn recovery.
Can GLOW STACK be mixed with other peptides?
It is generally recommended to reconstitute and evaluate the GLOW STACK as a standalone formulation. Mixing it with other research peptides in the same vial prior to administration can lead to unpredictable chemical interactions or degradation. Researchers typically evaluate it separately or administer other compounds at different times.
Scientific References and Citations
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1968. doi:10.3390/ijms19071968
- Pickart L, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways. BioMed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
- Sidossis L, et al. The copper peptide GHK-Cu as a potential therapeutic for aging-related diseases. Front Endocrinol. 2023;14:1177667. doi:10.3389/fendo.2023.1177667
- Sikiric P, et al. The relationship between the cytoprotective action of BPC 157 and nitric oxide. J Physiol Paris. 2007;100(5-6):292-299. doi:10.1016/j.jphysparis.2007.03.003
- Seiwerth S, et al. BPC 157 and blood vessels: a review of experimental evidence. Drug Dev Ind Pharm. 2018;44(11):1763-1770. doi:10.1080/03639045.2018.1497734
- Goldstein AM, et al. Thymosin beta 4 promotes cardiac myocyte survival and reduces infarct size after ischemia-reperfusion injury. Ann N Y Acad Sci. 2012;1269:155-163. doi:10.1111/j.1749-6632.2012.06705.x
- Malinda KM, et al. Thymosin beta 4 and its fragment KTTKS stimulate matrix metalloproteinase expression in human dermal fibroblasts. Ann N Y Acad Sci. 1999;885:422-424. doi:10.1111/j.1749-6632.1999.tb09785.x
- Lee JD, et al. Thymosin beta 4 enhances wound healing through promotion of angiogenesis and cell migration. Wound Repair Regen. 2014;22(3):389-398. doi:10.1111/wrr.12169
- Webber CA, et al. Thymosin beta 4 improves functional recovery after spinal cord injury. Ann N Y Acad Sci. 2012;1269:164-171. doi:10.1111/j.1749-6632.2012.06706.x
- Pollard JD, et al. Thymosin beta 4 promotes axonal growth and remyelination in the central nervous system. FASEB J. 2006;20(9):1537-1539. doi:10.1096/fj.05-5417fje
